July 2024
FPN staff recently celebrated another terrific meeting in Montreal, Quebec, Canada, hosted by the Peripheral Nerve Society from June 22-25. Many research conversations took place, specifically concerning our biobank’s newest discoveries and an update on progress made towards the iMAGiNE Study research project that we fund. We look forward to sharing more details about new research underway in our upcoming issues – stay tuned and stay hopeful!
CRTS grant applications are now open
Applications for our Clinical Research Training Scholarships (CRTS) in peripheral neuropathy, which provide research grants to young investigators, are now open!
Interested in applying? Learn more.
Reminder: Join us for the FPN Summer Web Series!
Discover valuable insights and support through our new Summer Web Series, running from July 9 to August 1. This 6-part series features expert-led sessions on essential topics like understanding peripheral neuropathy, managing treatments, and real stories of resilience and hope from those living with the condition.
Don’t miss out on this opportunity to connect, learn, and engage with experts and fellow community members! RSVP for one or all sessions today! Can’t attend live? Sign up anyway and get easy access to the recording link after the program.
Your participation supports our mission; a suggested $25 donation helps us continue hosting events like this web series.
Neuromuscular training decreased incidence of CIPN
Read how two types of exercises versus the usual care can significantly reduce the incidence of chemo-induced neuropathy, according to this article published by MedPageToday.
A randomized trail shows that a specific exercise regimen not only presents potentially the best current treatment option for CIPN, but also has the potential to prevent CIPN, improve quality of life, and have a positive impact on the course of oncological treatment.
On a related subject, please watch our webinar on alternative therapies that enhance balance.
hATTR amyloidosis: Ocular symptoms and solutions
Hereditary transthyretin (hATTR) amyloidosis is a genetic disease characterized by toxic clumps of transthyretin protein that cause damage to the body’s tissues. The disease can affect many parts of the body, most often the nerves and heart, but also other areas such as the eyes.
To learn more about hATTR and ocular symptoms and solutions, read this article recently published in FAP News Today.
Reduced risk to PN tied to Diabetic medication
A medication that has shown significant benefits in diabetes and obesity, called tirzepatide, may also help prevent diabetic peripheral neuropathy (DPN), new research suggests.
In a large database analysis of patients with type 2 diabetes, those taking tirzepatide had a significantly reduced risk for DPN over 2 years compared with their counterparts who were on insulin or other diabetes medications.